2.2 Conservative Management, Non-Pharmacologic & Pharmacologic Therapies for OA

2.2 Conservative Management, Non-Pharmacologic & Pharmacologic Therapies for OA

Core Practice Guideline: Both the American Academy of Orthopaedic Surgeons (AAOS) and the American College of Rheumatology (ACR) establish that non-pharmacologic modalities must be initiated as the foundational baseline for all patients with osteoarthritis. Pharmacologic agents are introduced in a tiered, risk-stratified manner to supplement lifestyle and physical interventions, prioritizing localized topical agents before advancing to systemic oral medications.

---

Evidence-Based Non-Pharmacologic Foundations

Non-pharmacologic interventions modify joint biomechanics, enhance periarticular dynamic stability, and mitigate systemic inflammatory drivers.

Multimodal Non-Pharmacologic Management Strategy
├── Biomechanical Unloading
│   ├── Weight Loss: Target ≥5% to 10% total body weight reduction
│   ├── Contralateral Cane Ambulation: Offloads joint contact force by ~50%
│   └── Compartmental Unloader Bracing: Corrects varus/valgus coronal malalignment
├── Physical & Aquatic Conditioning
│   ├── Low-Impact Aerobic Exercise (Cycling, Walking, Elliptical)
│   ├── Aquatic Therapy (Buoyancy unloads 50% to 90% of gravitational weight)
│   └── Resistance Training (Quadriceps & Hamstrings Isometrics / Closed-Chain Exercises)
└── Biomechanical Orthotics
    ├── Lateral Wedge Insoles (for medial compartment OA with mild varus)
    └── Hand Splinting (1st CMC immobilization during painful exacerbations)

1. Weight Loss Biomechanics

In weight-bearing joints, especially the knee and hip, reducing body weight yields exponential reductions in joint compressive stress. During normal level walking, every 1 pound of weight loss removes approximately 4 pounds of compressive force from the tibiofemoral joint per stride. Across an average 5,000-step day, a 10-pound weight reduction eliminates 200,000 pounds (100 tons) of cumulative mechanical load. Achieving a ≥5% to 10% weight loss significantly improves Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain and physical function scores.

2. Exercise & Aquatic Therapy Protocols

• Aquatic Therapy: Immersion to the xiphoid process unloads approximately 60% to 75% of body weight, and immersion to the neck unloads 90%. This permits active range of motion and resistive muscle strengthening without provocative joint impaction.
• Low-Impact Aerobic & Resistance Conditioning: Enhances synovial fluid circulation and cartilage nutrition through cyclic imbibition. Quadriceps strengthening is paramount; quadriceps weakness is an independent, modifiable risk factor for accelerated knee cartilage degeneration.
• Assistive Device Education (Contralateral Cane): When using a single-point cane, patients must hold the cane in the hand contralateral (opposite) to the affected lower extremity. Advancing the cane simultaneously with the affected limb broadens the base of support and reduces the required abductor muscle force (gluteus medius/minimus), lowering the resultant hip and knee joint reaction force by up to 50%.

---

Stepwise Pharmacologic Ladder & Topical NSAIDs

When non-pharmacologic modalities provide incomplete symptom control, pharmacotherapy is layered in a stepwise, risk-stratified sequence:

Pharmacologic Treatment Hierarchy for Osteoarthritis

  [Step 1: First-Line Topical Agents] ──── Diclofenac Sodium 1% Gel / 1.3% Patch / Capsaicin
                     │
  [Step 2: Risk-Stratified Oral NSAIDs] ── Oral NSAID (Lowest Dose, Shortest Duration) 
                     │                     + PPI Gastroprotection or COX-2 Selective (Celecoxib)
  [Step 3: Central Pain Modulator] ─────── Duloxetine (SNRI for central sensitization / nociplastic pain)
                     │
  [Avoided / Highly Restricted] ───────── Chronic Oral Opioids (Contraindicated for routine management)

Topical NSAIDs: The Guideline-Preferred First-Line Agent

Topical NSAIDs, such as diclofenac sodium 1% gel or diclofenac 1.3% transdermal patch, are strongly recommended over oral NSAIDs as initial pharmacotherapy for knee and superficial joint OA.

• Mechanism & Pharmacokinetics: Topical diclofenac penetrates through the skin into the subcutaneous tissue, synovial fluid, and articular cartilage, exerting local anti-inflammatory effects via cyclooxygenase inhibition. Systemic bioavailability is only 1% to 10% of an equivalent oral dose.
• Clinical Efficacy & Safety: Achieves pain relief equivalent to oral NSAIDs while dramatically minimizing systemic gastrointestinal, renal, and cardiovascular adverse events.
• Nursing Administration Points:
  • Use the manufacturer-provided dosing card (2 g for upper extremity joints; 4 g for lower extremity joints like the knee).
  • Do not apply to open wounds, infected skin, or concurrently with other oral NSAIDs without provider clearance.
  • Avoid applying external heat sources (e.g., heating pads) over topical patches or gel, which dramatically accelerates systemic absorption.

---

Oral NSAID Selection, COX Selectivity & Organ System Toxicity

Oral nonsteroidal anti-inflammatory drugs inhibit the cyclooxygenase enzymes (COX-1 and COX-2), blocking the conversion of arachidonic acid to pro-inflammatory prostaglandins:

---

Acetaminophen, Duloxetine & Central Pain Sensitization

The Diminishing Role of Acetaminophen (Paracetamol)

Historically considered first-line for OA, contemporary meta-analyses (including Cochrane reviews and OARSI guidelines) demonstrate that acetaminophen has a clinically negligible effect size (standardized mean difference <0.2) in osteoarthritis pain reduction.

• Safety Ceilings: Absolute maximum daily ceiling is 3,000 mg/day in healthy adults, and 2,000 mg/day in older adults, frail patients, or those with chronic alcohol use or mild-to-moderate hepatic impairment.
• Nursing Surveillance: Educate patients to cross-check over-the-counter (OTC) combination cough/cold or sleep medications for hidden acetaminophen to prevent accidental hepatotoxicity.

Duloxetine: Targeting Nociplastic Pain & Central Sensitization

Chronic osteoarthritis often transitions from purely nociceptive joint pain to a state of central sensitization (augmented central pain processing, hyperalgesia, and impaired descending inhibitory pathways).

• Mechanism of Action: Duloxetine (Cymbalta) is a Serotonin and Norepinephrine Reuptake Inhibitor (SNRI) that potentates descending noradrenergic and serotonergic pain inhibitory pathways within the dorsal horn of the spinal cord.
• Indications: Recommended by ACR guidelines as an effective adjunct for knee, hip, and multi-joint OA, particularly when NSAIDs are contraindicated (e.g., severe CKD, peptic ulcer disease, advanced heart failure) or when centralized pain features (widespread hypersensitivity, sleep disturbance) predominate.
• Dosing & Nursing Monitoring: Initiated at 30 mg orally once daily for 1 week to minimize nausea, then titrated to a target dose of 60 mg daily. Monitor for dry mouth, constipation, dizziness, somnolence, and educate regarding the risk of serotonin syndrome when combined with other serotonergic medications.

---

Opioid Stewardship in Osteoarthritis

Major orthopaedic and rheumatology clinical practice guidelines (AAOS, ACR, OARSI, CDC) strongly advise against the routine prescription of chronic oral opioids (e.g., oxycodone, hydrocodone, morphine, tramadol) for osteoarthritis.

Clinical Rationale Against Chronic Opioid Therapy in Osteoarthritis:
├── Lack of Long-Term Efficacy: No clinically meaningful functional improvement beyond 6-12 weeks
├── Neurobiological Risks: Rapid tolerance development, physical dependence, and Opioid-Induced Hyperalgesia (OIH)
├── Geriatric Vulnerabilities: Excessive sedation, cognitive blunting, constipation, urinary retention, respiratory depression
└── Orthopaedic Morbidities: 2- to 3-fold increase in fall risk, resulting in fragility fractures (femoral neck, spine)

Opioid administration in OA is restricted solely to short-term rescue (typically <3 to 7 days) during acute, severe, disabling flares when all first-line non-pharmacologic and non-opioid medications are strictly contraindicated, with a mandatory predefined exit and weaning strategy.